How Evolocumab (Repatha) Affects ALT Levels
Clinical evidence on Repatha's effect on ALT, including data from FOURIER and post-market surveillance. Learn monitoring protocols, expected changes, and when to act on liver enzyme shifts.
How Evolocumab Affects Labs
4 source-based articles maintained by the HealthRX.com Editorial Team.
4articles
1topic areas covered
May 26, 2026latest review
How Evolocumab Affects Labs library
Showing 4 of 4 clinical reviews.
How Evolocumab (Repatha) Affects ApoB Levels
Evolocumab (Repatha), a PCSK9-inhibiting monoclonal antibody, lowers apolipoprotein B through increased LDL receptor recycling. This article reviews what trial and mechanistic evidence supports, what remains unverified, and how ApoB tracking should inform monitoring.
How Evolocumab (Repatha) Affects AST Levels
Clinical evidence on Repatha's effect on AST liver enzymes, including data from FOURIER and post-market surveillance, with monitoring recommendations.
How Evolocumab (Repatha) Affects Your Standard Lipid Panel
Evolocumab (Repatha) produces dramatic changes across every line of a standard lipid panel. This evidence-based guide covers LDL-C, HDL-C, triglycerides, total cholesterol, magnitude of change, time course, and monitoring schedules.